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        Control of viral replication after infection has 
been attributed, at least in part, to CTL (CD8  +  ) 
activity (  1  ). Although all infected individuals 
can mount HIV-specifi  c CTL responses, sus-
tained, near-complete, viral control is only evi-
dent in a few who are recognized as aviremic 
controllers (  2  ). Progression to AIDS occurs in 
the vast majority of untreated HIV infected pa-
tients, and this loss of immune control is partly 
caused by CTL escape mutations (  3  ). Escape 
mutations modify a viral genome during infec-
tion for optimal replication in the absence of an 
immune response. Thus, CTLs targeting struc-
turally or functionally conserved epitopes might 
benefit the host by diminishing the ability 
of the virus to develop escape mutations while 
at the same time retaining replicative fi  tness. 
Independent studies have demonstrated that 
CTLs directed against Gag, a relatively con-
served protein with structurally critical do-
mains, correlate with improved clinical markers 
of disease progression (  4, 5  ). A recent study 
of   >  500 antiretroviral therapy naive HIV-1 pa-
tients in South Africa demonstrated that the 
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  In a study of 114 epidemiologically linked Zambian transmission pairs, we evaluated the 
impact of human leukocyte antigen class I (HLA-I)  –  associated amino acid polymorphisms, 
presumed to refl  ect cytotoxic T lymphocyte (CTL) escape in Gag and Nef of the virus trans-
mitted from the chronically infected donor, on the plasma viral load (VL) in matched recip-
ients 6 mo after infection. CTL escape mutations in Gag and Nef were seen in the donors, 
which were subsequently transmitted to recipients, largely unchanged soon after infection. 
We observed a signifi  cant correlation between the number of Gag escape mutations tar-
geted by specifi  c HLA-B allele  –  restricted CTLs and reduced VLs in the recipients. This 
negative correlation was most evident in newly infected individuals, whose HLA alleles were 
unable to effectively target Gag and select for CTL escape mutations in this gene. Nef 
mutations in the donor had no impact on VL in the recipient. Thus, broad Gag-specifi  c CTL 
responses capable of driving virus escape in the donor may be of clinical benefi  t to both 
the donor and recipient. In addition to their direct implications for HIV-1 vaccine design, 
these data suggest that CTL-induced viral polymorphisms and their associated in vivo viral 
fi  tness costs could have a signifi  cant impact on HIV-1 pathogenesis. 1010 IN VIVO FITNESS COSTS ASSOCIATED WITH HIV-1 GAG CTL ESCAPE MUTATIONS | Goepfert et al.
African patients with chronic HIV-1 infection and sequenced 
the   gag   and   nef   genes of their circulating virus (unpublished 
data) (  12, 15  ). Associations were corrected for viral phy-
logeny, as this approach was shown to signifi  cantly improve 
the specifi  city of HLA-I associations (  16, 17  ). We limited 
our initial analysis to HLA-I viral polymorphisms that oc-
curred within or fl  anked (within fi  ve amino acids of the 
N or C termini of the epitope) known HLA-I  –  restricted CTL 
epitopes. Such HIV-1 polymorphisms are more likely to 
represent CTL escape and less likely to represent confound-
ing secondary compensatory mutations (  11, 13, 14  ). These 
analyses resulted in the identifi  cation of 20 mutations within 
Gag (18 within p24) and 11 within Nef (  Table I  ).   The ma-
jority of the mutations within Gag (17 out of 20; 85%) and 
Nef (8 out of 11; 73%) were HLA-B restricted. Of those 
mutations that have been fully evaluated, all (fi  ve in Gag and 
two in Nef) were formally shown to be CTL escape variants 
(  12, 15, 18  –  20  ). 
  We then applied these HLA-I  –  associated polymorphisms, 
found in chronic infection, to the analyses of early HIV-1 
transmission within a cohort of 114 epidemiologically linked 
Zambian transmission pairs. These couples were initially iden-
tifi  ed as HIV-1 discordant (i.e., one partner was HIV-1 in-
fected and their spouse was uninfected). Despite counseling 
and condom provision, transmission from the chronically in-
fected partner to their spouse continues, but at a signifi  cantly 
reduced rate (    8% per year) (  21  ). Epidemiological linkage of 
the transmission pairs was established through sequence analysis 
of the regions encoding gp41 and Gag (  22  ). Population-based 
best level of viral control occurred in patients who targeted 
Gag-specifi  c CTL epitopes that are presented by specifi  c HLA 
class I (HLA-I) alleles (  6  ). In many cases, such targeting leads 
to the selection of specifi  c HLA-I  –  associated amino acid poly-
morphisms that result in reduced epitope recognition (  1  ). 
It remains unclear whether the clinical benefi  t observed in 
these individuals is caused by the quality of the immune re-
sponses, to viral fi  tness constraints resulting from CTL escape, 
or to both. 
  Evidence that it is a combination of these factors that re-
sults in reduced plasma viral load (VL) is supported by studies 
in individuals who carry certain HLA class I alleles and who 
control HIV well in the absence of antiretroviral therapy. 
HLA-B*57 and HLA-B*27, in particular, have been consis-
tently associated with improved markers of clinical outcome 
and slower rates of progression to AIDS (  7  ). HIV-specifi  c 
CTLs restricted by these two HLA molecules dominate in 
individuals expressing these alleles (  8  ), with Gag being the 
major CTL target. Distinct qualitative diff  erences have been 
demonstrated in CTLs restricted by HLA-B*57 (  9  ) or HLA-
B*27 (  10  ). Recent studies demonstrate reversion of CTL 
  escape mutations upon transmission into a new host in the 
absence of HLA-mediated selection pressure (  11, 12  ). These 
in vivo fi  ndings have been supported by in vitro studies 
showing a reduced replication capacity of viruses with certain 
CTL escape mutations (  13, 14  ). Nevertheless, none of these 
mutations have been shown to negatively aff  ect VL or mod-
ify other biological markers of clinical outcome in chronic 
infection. One explanation may be that CTL escape muta-
tions, which reduce the immunological suppression of virus 
replication (  3  ), can simultaneously reduce the replication ca-
pacity of the virus (  11, 13, 14  ). In other words, although a 
CTL escape mutation may result in a reduced viral replica-
tion capacity, it is not likely that this will result in a lower VL 
in the chronically infected host, where this mutation was in-
duced, because the virus is gaining a fi  tness advantage by 
avoiding CTLs. Such fi  tness eff  ects may therefore only be 
evident upon transmission to a recipient lacking the same re-
stricting HLA-I molecule. 
  In this report, we took advantage of the HLA-I  –  associ-
ated HIV-1 polymorphisms that had been defi  ned in Gag and 
Nef from studies of a large South African cohort with chronic 
clade C infection (unpublished data). We used this informa-
tion to study  —  in a cohort of epidemiologically linked, clade 
C  –  infected Zambian HIV-1 transmission pairs  —  the eff  ects 
of mutations induced in the transmitted virus by donor CTLs 
on an early VL set point in the newly infected recipient. Our 
fi  ndings suggest that HLA-B  –  restricted mutations in Gag, 
but not Nef, result in a reduced VL upon transmission, and 
directly demonstrate for the fi  rst time in vivo that a clinically 
signifi  cant viral fi  tness cost is induced when the virus escapes 
immune recognition by donor CTLs. 
    RESULTS AND DISCUSSION   
  To identify HLA-I  –  associated HIV-1 subtype C polymor-
phisms, we performed HLA-I typing on 701 untreated South 
    Figure 1.         Southern African clade C Gag sequences tend to cluster 
together.   Neighbor-joining phylogenetic tree of Gag (p17 and p24) clade 
C taxa is shown. These taxa (20 from each cohort) were randomly selected 
from the total pool of sequencing data available from the South African 
(ZA, yellow) and Zambian (ZM, red) cohorts. We used an HIV database 
(  Table I  ) to obtain clade C consensus and sequences from other countries 
affected by the clade C epidemic. Other African countries are shown 
(blue), with 10 sequences each from Botswana (BW), Kenya (KE), and 
Malawi (MW), and 6 sequences from Zimbabwe (ZW). Non-African taxa 
(green) are represented by 10 sequences each from India (IN) and Brazil 
(BW). Bootstrap values   >  70% are shown.     JEM VOL. 205, May 12, 2008  1011
BRIEF DEFINITIVE REPORT
this region. This is supported by previous experiments that 
have reported the identical escape mutations selected in geo-
graphically distinct but otherwise similar clade B  –  infected 
cohorts (  12  ). 
  After HLA-I typing of both partners from each of the 114 
epidemiologically linked Zambian transmission pairs, plasma 
VL was determined from the same samples that viral   gag   and 
  nef   gene sequences were derived. We examined the relation-
ship of amino acid polymorphisms in Gag and Nef sequences 
to early VL in the newly infected partners of this Zambian 
transmission pair cohort. We reasoned that early VL (after 
seroconversion) would be more refl  ective of the characteristics 
sequencing of   gag   and   nef   genes was performed on DNA 
RT-PCR amplifi  ed from plasma virus RNA obtained     6 mo 
after the estimated date of infection. A phylogenetic tree, 
constructed to determine the relationships of HIV-1   gag   gene 
sequences between the two cohorts studied in this paper and 
other clade C sequences derived from the Los Alamos National 
Laboratory HIV Molecular Immunology Database (  Fig. 1  ), 
demonstrated that Southern African sequences tend to cluster 
together, distinct from those prevalent in representative coun-
tries in East Africa, South America, and Asia.   These data sug-
gest that sequence analyses derived from one country may be 
closely applicable to viruses found in neighboring countries in 
    Table I.        HLA class I allele  –  associated HIV-1 polymorphisms occurring within or fl  anking known CTL epitopes in chronically clade 
C – infected  South  Africans 
HIV-1 subregion Common mutations    a   Defi  ned epitopes    b   Specifi  c HLA-I association    c   
Gag-p17 EKI RLRPGGKK      H      Y ML RY10 (Gag 20  –  29) B*4201, P = 1.1   ×   10      4  ; q = 0.07
EKI RLRPGGKKHY    M  L RY10 (Gag 20  –  29) B*4201, P = 1.7   ×   10      4  ; q = 0.17
Gag-p24 HQ  A    ISPRTLNAW VKV IW9 (Gag 147  –  155) B*5703, P = 2.5   ×   10      14  ; q = 0
HQA    I      SPRTLNAW VKV IW9 (Gag 147  –  155) B*5703, P = 1.6   ×   10      8  ; q = 0
QAI SPRTLNAWV KV  I  SV9 (Gag 148  –  156) B*8101, P = 2.8   ×   10      3  ; q = 0.15
IEE K      A   FSPEVIPMF T KF11 (Gag 162  –  171) B*5703, P = 1.4   ×   10      15  ; q = 0
IEE KAF      S      PEVIPMF T KF11 (Gag 162  –  171) B*5703, P = 2.9   ×   10      4  ; q = 0.04
  E GA TPQDLNTML NTV TL9 (Gag 180  –  188) B*8101, P = 4.3   ×   10      7  ; q = 0
EGA TP      Q      DLNTML NTV TL9 (Gag 180  –  188) B*8101, P = 3.6   ×   10      5  ; q = 0.01
EGA TPQD      L      NTML NTV TL9 (Gag 180  –  188) B*8101, P = 1.9   ×   10      3  ; q = 0.11
AGT TS      T   LQEQIAW MT  TW10 (Gag 240  –  249) B*57/5801, P = 1.9   ×   10      28  ; q = 0
AGT TSTLQEQ      I      AW MT TW10 (Gag 240  –  249) B*5703, P = 1.7   ×   10      5  ; q = 0
TSN PPIPVG      D      IY KRW PY9 (Gag 254  –  262) B*35, P = 1.1   ×   10      7  ; q = 0
DYV DRFF   K   TLRA EQA DA9 (Gag 298  –  306) B*1401, P = 2.5   ×   10      11  ; q = 0
FRD YVDRFFK   T   L  R A E YL9 (Gag 296  –  304) Cw*0304, P = 3   ×   10      4  ; q = 0.04
RAE QA      T      QDVKNW MTD QW9 (Gag 308  –  316) B*5801, P = 3.7   ×   10      7  ; q = 0
R AEQATQ      D      VKNW MTD AW11 (Gag 306  –  316) B*4403, P = 3   ×   10      9  ; q = 0.03
TIL R      A   LGPGATL EEM RL9 (Gag 335  –  343) Cw*08, P = 9.3   ×   10      4  ; q = 0.09
TIL RALG      P      GATL EEM RL9 (Gag 335  –  343) Cw*08, P = 8.5   ×   10      4  ; q = 0.09
GVG GP      G   HKARVL AEA GL9 (Gag 355  –  363) B*0702/05, P = 6.7   ×   10      10  ; q = 0.03
Nef EEE E      E      VGFPVRPQV P EV11 (Nef 65  –  75) B*4501, P = 8.3   ×   10      9  ; q = 0
FPV    R      PQVPLRPM TYK RM9 (Nef 72  –  80) B*0702, P = 10      9  ; q = 0
FPV RPQVP      L      RPM TYK RM9 (Nef 72  –  80) B*8101, P = 1.8   ×   10      10  ; q = 0
RPQ VPLRPMT      Y    KAAF VY8 (Nef 74  –  81) B*35, P = 1.1   ×   10      7  ; q = 0
MTY K   A      AFDLSFF LKE KF9 (Nef 82  –  90) B*57/5801, P = 7.3   ×   10      6  ; q = 0.07
FFL KEKGGLEGL I  Y  S KL9 (Nef 91  –  100) B*4403, P = 1.9   ×   10      8  ; q = 0
YSK  K      RQEILDLWVY H KY11 (Nef 105  –  115) Cw*0701, P = 7.9   ×   10      7  ; q = 0
YSK KRQ   E      ILDLWVY H KY11 (Nef 105  –  115) B*18, P = 1.4   ×   10      9  , q = 0
G  V  R YPLTFGWCF KLV YF9 (Nef 135  –  143) B*35, P = 6.7   ×   10      6  ; q = 0
PGV R      Y      PLTFGW CFKL RW8 (Nef 134  –  141) A*2402, P = 10      4  ; q = 0.20
PGV RYPLTFGW C F  KL RW8 (Nef 134  –  141) A*2301, P = 6.8   ×   10      12  ; q = 0
These data are taken from 59 HLA associations (q   <   0.2) defi  ned in a clade C South African cohort (unpublished data), in which analysis of   gag   sequences was performed 
using data from 672 study subjects and analysis of   nef   sequences was performed using data from 443 study subjects. The Los Alamos National Laboratory HIV Molecular 
Immunology Database (available at http://www.hiv.lanl.gov/content/index) was used to defi  ne known CTL epitopes.
  a  HLA-associated mutations (bolded) shown in the context of the known CTL epitopes (underlined).
  b Defi  ned CTL epitopes with amino acid residues based on the HXB2 sequences in parentheses.
  c  Methods for calculating p- and q-values have been previously described (reference   16  ).1012 IN VIVO FITNESS COSTS ASSOCIATED WITH HIV-1 GAG CTL ESCAPE MUTATIONS | Goepfert et al.
in recipient partners. Accumulation of HLA-I  –  associated 
polymorphisms in Nef was not linked to either a higher or 
lower VL in recipients (     = 0.01; NS;   Fig. 2 A  ).   In contrast, 
a higher number of HLA-I  –  associated mutations within Gag 
was signifi  cantly associated with lower VL (     =     0.27; P = 
0.01;   Fig. 2 B  ). 
  Although limiting the HLA-I  –  associated HIV-1 polymor-
phisms to those occurring within or fl  anking known CTL ep-
itopes strengthens the case that these changes represent CTL 
escape mutations, it potentially introduces selection bias into our 
dataset. We therefore included all HLA-I  –  associated polymor-
phisms (P   <   0.001; q   <   0.2) whether or not they were coupled 
of the virus transmitted from the donor than VL seen later 
during chronic infection, when reversion and compensatory 
mutations might occur. Indeed, the majority of HIV-1 poly-
morphisms (579 out of 610; 94.9%) were identical in the do-
nor and recipient at 6 mo after transmission. Gag mutations 
were more likely to be unchanged in the recipient when 
compared with Nef mutations, because the latter had a greater 
tendency to exist as the clade C consensus amino acid in the 
recipient (97.1 vs. 91.3%, respectively; P = 0.002). 
  Next, we analyzed the relationship between the num-
bers of transmitted HLA-I  –  linked Gag and Nef mutations 
within or fl  anking known CTL epitopes (  Table I  ) to early VL 
    Figure 2.         HLA-B  –  associated mutations in donor Gag affect HIV-1 plasma VL in linked recipients.   (A and B) In linked recipients in the Zambian 
cohort (  n   = 114), the association between the numbers of mutations within or fl  anking known CTL epitopes (  Table I  ) in HIV-1 Nef (A) and Gag (B) with VL is 
shown. (C and D) All HLA-I  –  restricted polymorphisms associated with Nef and Gag mutations, respectively, were included (P   <   0.001 and q   <   0.2), regard-
less of whether they were within or fl  anking known CTL epitopes (  Table I   and Table S1). (E and F) all HLA-B  –  restricted mutations (P   <   0.001 and q   <   0.2) for 
Nef and Gag, respectively. The horizontal bars represent median VL values. The Mann-Whitney U test was used to compare median VL between groups, and 
the nonparametric Spearman rank correlation test was used to determine whether a correlation exists between the number of mutations and VL.     JEM VOL. 205, May 12, 2008  1013
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  These results (  Fig. 2 F  ) support previous studies demon-
strating that the HIV-1  –  specifi  c CTL responses with the 
greatest impact on VL are HLA-B restricted (  23  ) and are 
directed against Gag epitopes associated with CTL escape 
mutations (  6  ), perhaps refl  ecting the selection pressure im-
posed by these eff  ective responses. Thus, a confounding factor 
in this analysis of the in vivo fi  tness cost of escape mutations 
may be the new HIV-1  –  specifi  c CTL responses, certainly 
present a 6 mo after infection, which could by themselves 
reduce VL. This would imply that newly infected individ-
uals lacking the HLA-B molecules that drive CTL escape 
mutations in Gag (  Table I  ) would benefi  t most from the 
receipt of virus with detrimental escape mutations in Gag. 
When only these latter recipients were included in the anal-
ysis, the association between the increasing number of Gag 
mutations and reduced VL was much stronger (     =     0.57; 
P = 0.0003;   Fig. 3 A  ).   
  This fi  nding also suggests that the recipients who are able 
to eff  ectively target Gag themselves would derive less abso-
lute benefi  t from CTL-induced Gag mutations because of 
with known CTL epitopes (  Table I  ; and Table S1, available at 
http://www.jem.org/cgi/content/full/jem.20072457/DC1). 
This provided an additional 16 mutations in Gag and 12 muta-
tions in Nef. Unlike what was observed for mutations associated 
with known CTL epitopes, we saw a more even distribution of 
the HLA-I restriction of these mutations for both Gag (seven 
HLA-A, four HLA-B, and four HLA-C restricted) and Nef 
(four restricted by each HLA-I allele). No associations were 
seen when comparing the numbers of Nef mutations with VL 
(     = 0.01; NS;   Fig. 2 C  ), consistent with the previous analysis, 
and there was no longer a signifi  cant association with the total 
number of Gag mutations and VL (     =     0.11; NS;   Fig. 2 D  ). 
In contrast, when we focused the analysis on HLA-B  –  associated 
Gag polymorphisms, these remained signifi  cantly associated with 
diminished VL (     =     0.24; P = 0.02;   Fig. 2 F  ). HLA-A  –   and 
HLA-C  –  associated Gag polymorphisms were not associated 
with a lower recipient VL (     = 0.08; NS; unpublished data). 
Similarly, HLA-B  –  associated Nef mutations were not asso  ciated 
with either positive or negative VL changes in the recipients 
(     = 0.02; NS;   Fig. 2 E  ). 
    Figure 3.         Recipients lacking HLA-B alleles associated with Gag mutations benefi  t most from these mutations.   (A and B) The relationship be-
tween VL and HLA-B  –  associated polymorphisms in Gag is shown for recipients who lack (A) or carry (B) the HLA-B alleles associated with these mutations 
(  Table I  ). (C) The relationship between VL and the number of Gag epitopes that are potentially targeted in the same recipients as in B. Potential epitopes 
are defi  ned as the number of Gag polymorphisms that are associated with the HLA-B alleles of each recipient. Panel A represents 35 recipients, whereas 
B and C represent 50 recipients each. The horizontal bars represent median VL values. Statistics were performed as described in   Fig.  2 .   1014 IN VIVO FITNESS COSTS ASSOCIATED WITH HIV-1 GAG CTL ESCAPE MUTATIONS | Goepfert et al.
mutation results in a viral fi  tness cost in chronically infected 
patients. This current study is unique in that the identity of 
the transmitted virus was known in each of the individuals 
early after infection. This allowed us to observe the impact of 
HLA-I  –  induced mutations on virus replication after it entered 
a new immunogenetic environment where the fi  tness cost of 
the mutations would be most pronounced. Importantly, we 
demonstrate two diff   erent mechanisms of viral control in 
newly infected recipients. Similar to previous experiments (  6  ), 
those recipients expressing certain HLA-B alleles likely con-
trol VL by eff  ective CTL Gag targeting. In contrast, newly 
infected recipients who lack HLA-B alleles associated with 
Gag polymorphisms can derive signifi  cant benefi  t from the 
transmission of viruses containing Gag mutations induced in 
partners with potent HLA-B  –  restricted responses. 
  One possible explanation for the fi  nding that mutations in 
Gag, but not Nef, aff  ect viral fi  tness is that the former protein 
(and in particular p24) must make multiple interactions with 
other Gag molecules during the assembly of both immature 
viral capsids and mature viral cores, as well as with cellular 
components such as cyclophilin A (  25  ). This relative struc-
tural infl  exibility may allow the immune system, through its 
targeting of Gag, to signifi  cantly aff  ect viral replication, and 
would provide a strong mechanistic rationale for the repeated 
the equipoise between CTL-derived virus suppression and 
the fi  tness costs associated with escape mutations. Indeed, we 
did not see any association between the number of Gag 
mutations and VL in recipient carriers of HLA-B alleles that 
select for the Gag CTL escape mutations described in   Table I   
(     = 0.07; NS;   Fig. 3 B  ). To determine whether newly in-
duced Gag-specifi  c CTL responses could be contributing to 
VL control in this latter recipient group, the number of HLA-
B  –  restricted Gag epitopes that could potentially be targeted 
in each individual was quantifi  ed and compared with VL. 
In line with previous fi  ndings (  4, 6  ), the greater the number of 
Gag CTL epitopes potentially targeted by these recipients, the 
greater the decrease in VL (     =     0.28; P = 0.047;   Fig. 3 C  ). 
This latter fi  nding in recipients with Gag-specifi  c CTLs 
capable of inducing mutations is also similar to a recently 
published paper in which an inverse relationship was demon-
strated between VL and HLA-I  –  associated polymorphisms 
in Gag, Pol, and Nef in chronically infected hosts (  24  ). Our 
analysis expands on this study because CTL escape mutations 
induced by the recipient  ’  s immune system were almost non-
existent at the time point analyzed (unpublished data). There-
fore, it is likely that the potency of CTLs associated with 
mutations in Gag plays an important role in early viral con-
trol, even if these mutations do not occur. 
  Because certain HLA-B alleles are associated with im-
proved disease outcomes (  7, 23  ), it was important to consider 
the possibility that the signifi  cant associations with VL were 
driven by Gag mutations restricted only by those HLA-I alleles 
previously associated with a lack of disease progression (e.g., 
HLA-B*57 or -B*5801). We therefore stratifi  ed the data accord-
ing to which HLA-I  –  associated Gag mutation was present 
in recipients who lacked HLA-B alleles that drive escape 
(  Fig. 4  ).   Although none of the VL associations with any indi-
vidual HLA-I allele were statistically signifi  cant, certain pat-
terns could be seen. All 12 HLA-B  –  associated Gag mutations 
were linked to lower VLs in HLA-mismatched recipients 
(compared with only one out of fi  ve HLA-A  –   or HLA-C  – 
associated mutations; P = 0.002). Of note, this trend was not 
unique to HLA-B alleles associated with good clinical markers, 
but instead was also observed with HLA-B*07, -B*35, -B*41, 
and -B*44. These data suggest that it is number of CTL epi-
topes targeted by any individual HLA allele (as assessed by the 
frequency of Gag mutations induced) that drives its association 
with lower VL. Notably, 13 out of 20 (65%) of the mutations 
in Gag (  Table I  ) were restricted by HLA molecules (HLA-
B*42, -B*57, -B*5801, and -B*8101) previously associated 
with lower VLs and a better clinical outcome (  7, 23  ). 
  Previous studies have examined VL diff  erences based on 
CTL escape that occurs during the course of chronic infec-
tion. These analyses are complicated by the fact that the oc-
currence of a CTL escape mutation in an individual abolishes 
immunological suppression of viral replication in that indi-
vidual. Indeed, escape from an HLA-B*27  –  restricted Gag re-
sponse results in a higher VL (  3  ) despite the fact that it is 
associated with reduced replicative capacity in vitro (  14  ). It is 
therefore diffi   cult to assess whether any particular escape 
    Figure 4.         Lower VL in recipients is not restricted to a select class 
of donor HLA-B alleles.   VLs based on transmission of viruses with 
(closed squares) or without (open squares) Gag mutations restricted by 
individual HLA-I alleles are shown. The data represent only recipients (  n   =  36) 
who do not express HLA-B molecules associated with Gag polymorphisms, 
as shown in   Table I  . Only mutations present in at least two of the recipi-
ents are shown. The Gag mutation restricted by either HLA-B*13 or -Cw*02 
could not be resolved to either individual allele. Squares represent median 
values, and error bars represent the interquartile range of the data.     JEM VOL. 205, May 12, 2008  1015
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  MATERIALS AND METHODS 
  Patients.     The South African cohort consisted of 680 patients with chronic 
HIV-1 infection from Durban, South Africa (  6, 23  ). The Zambian partici-
pants included 114 transmission pairs, shown to have epidemiologically 
linked HIV-1, from the Zambia-Emory HIV Research Project (  21, 22  ). All 
patients in both cohorts were antiretroviral therapy naive. Zambian linked 
recipients were identifi  ed at 5.6 mo (mean; median = 3.1 mo) after the esti-
mated time of infection, at which time plasma samples were obtained from 
both the donor and the recipient. All research protocols were approved by 
the ethics committees in Durban, South Africa and Lusaka, Zambia, and by 
the Emory University and Oxford University Institutional Review Boards. 
  HIV-1 sequencing.     Viral RNA from Zambian samples was extracted from 
200   μ  l of plasma using a robotic system with the MagNA Pure LC Total 
Nucleic Acid Isolation Kit (Roche). 10 and 1   μ  l RNA were amplifi  ed using a 
one-step RT-PCR high fi  delity kit (Invitrogen) for the RT and fi  rst-round 
amplifi  cation steps using gene-specifi  c primers. Gag primers included (forward) 
5    -ATTTGACTAGCGGAGGCTAGAA-3     and (reverse) 5    -GACAGGTG-
TAGGTCCTACTAATACTGTACC-3    . Nef primers included (forward) 
5    -AATAGAGTTAGGCAGGGATAC-3     (  32  ) and (reverse) 5    -GCACT-
CAAGGCAAGCTTTATTGAGGCTTA-3    . For nested PCR reactions, 
primer sequences for   gag   amplifi  cation were (inner forward) 5    -TTTGAC-
TAGCGGAGGCTAGAAGGA-3     and (inner reverse) 5    -GTATCATCT-
GCTCCTGTGTCTAAGAGAGC-3    . The primer sequences for   nef   gene 
amplifi  cation were (inner forward) 5    -GAGAGACTTCATATTGGTTG-
CAGCG-3     (a gift from S. Mallal, Murdoch University, Murdoch, Australia) 
and (inner reverse) 5    -AAAGCAGCTGCTTATATGCAGCATCT-3    . PCR 
products were purifi  ed using Montage MultiScreen PCR  96   fi  ltration plates 
(Millipore), and amplicons were sequenced by Macrogen. Sequences were ana-
lyzed using Sequencher 4.7 software (Gene Codes Corp.). Multiple peaks were 
recorded using International Union of Pure and Applied Chemistry codes 
whenever the lower peak level exceeded one third of the level of the maxi-
mum peak, and nucleotide sequences were then converted to amino acid 
sequences using the universal code. We also performed   gag   sequencing of mul-
tiple single genomes from both the donor and the recipient (mean = 20 clones 
in each group) in a subset of 11 transmission pairs. The consensus sequencing 
method mirrored the major polymporphisms transmitted from the donor to 
the recipient (unpublished data). HIV-1 sequencing of South African plasma 
samples was performed in a similar fashion (unpublished data). 
  Plasma VL.     Plasma VL was determined at the Emory Center for AIDS 
Research Virology Core Laboratory using the Amplicor HIV-1 Monitor Test 
(version 1.5; Roche). 
  HLA class I typing.     Using genomic DNA prepared from whole blood or 
buff  y coats (QIAamp blood kit; QIAGEN), HLA class I genotyping relied 
on a combination of PCR-based techniques, including PCR with se-
quence-specifi  c primers (Invitrogen) and reference-strand conformation 
analysis (Invitrogen), as described previously (  33  ). Ambiguities were re-
solved by sequencing-based typing using kits (Abbott Molecules, Inc.) de-
signed for capillary electrophoresis and the ABI 3130  xl   DNA Analyzer 
(Applied Biosystems). 
  Calculation of HLA-I  –  associated HIV polymorphisms.     We used a 
method similar to those previously described (  16, 34  ) to identify HLA-I  – 
associated HIV polymorphisms. This approach corrected for the phylogenetic 
structure of the sequences. Additionally, we included multiple HLA predic-
tors, allowing for the elimination of spurious associations caused by HLA 
linkage disequilibrium. In brief, for both Gag and Nef, a maximum likeli-
hood phylogenetic tree was constructed from the corresponding sequences. 
For every HLA allele, amino acid position, and amino acid at that position, 
two generative  —  or directed graphical  —  models of the observed presence or 
absence of the amino acid in each sequence were created: one represented the 
null hypothesis that the observations are generated by the phylogenetic tree 
alone, and the other represented the alternative hypothesis that additional 
observation that Gag-specifi  c CTLs correlate with biological 
markers of improved clinical outcome (  4  –  6  ). 
  It is not clear why HLA-B  –  restricted responses directed 
against HIV-1 play such an important role in immunopatho-
genesis, although several groups have demonstrated this asso-
ciation (  6, 8, 23  ). It is possible the HLA-B alleles just happen 
to target important regions in p24 with a higher binding 
affi   nity (  26  ). Furthermore HLA-A, -B, and -C are diff  eren-
tially expressed depending on the cell type (  27  ), and it is plau-
sible that certain antigen-presenting cells preferentially express 
HLA-B molecules. In addition to CTL function, HLA-B Bw4 
interacts with NK cells, and this was recently demonstrated to 
play an important role in HIV-1 control (  28  ). 
  The     10-fold VL reduction associated with increasing 
numbers of escape mutations (fewer than two versus more 
than six Gag mutations;   Fig. 3 A  ) observed in this report may 
be clinically signifi  cant, because even a 2.5-fold lower VL 
among recent HIV-1 seroconverters was associated with a 
benefi  t in AIDS-free survival (  29  ). Compensatory mutations 
(  11, 13  ) or reversions (  30  ) occurring after our analyzed time 
point could dampen the impact of CTL escape on viral fi  tness 
constraints. Follow-up VL data were available for 39 recipi-
ents at     1 yr after seroconversion or 6 mo after the fi  rst eval-
uation. Although the VL signifi  cantly increased at the second 
time point compared with the fi  rst (70,928 vs. 21,961 copies/ml, 
respectively; P   <   0.0001 using the Wilcoxon signed-rank 
test), it was higher in all patients irrespective of the number of 
Gag polymorphisms or whether or not the patients carried the 
  “  protective  ”   HLA-I alleles. Therefore, it is diffi   cult to know 
whether the increase in plasma VL seen after the fi  rst year of 
infection is caused by the development of compensatory muta-
tions, the loss of immune control, or other factors. Never-
theless, these HLA-I  –  induced mutations are certainly present 
at the earliest point of infection and would be expected to also 
infl  uence peak VL. Because much of the CD4 depletion oc-
curs before seroconversion (  31  ), these viral fi  tness mutations 
may contribute to long-lasting clinical benefi  t even if their 
biological impact is lost at some point after seroconversion. 
It would have been interesting to evaluate the impact of viral 
fi  tness mutations on CD4 T cells; however, this clinical test 
was not available at the time of the study. 
  Although these fi  ndings need to be replicated in other 
cohorts, they strengthen the argument for CTL targeting of 
Gag antigens as an important mechanism for sustained viral 
control. Moreover, if a virus encoding escape mutations in 
  gag   were to be transmitted to a new host in the absence of 
fully compensatory mutations (as observed in this report), 
these new recipients would likely benefi  t as well. These data 
imply that for CTL-based HIV vaccines to eff  ectively control 
VL, they must simultaneously target multiple Gag epitopes, 
thereby ensuring that fi  tness constraints prevent the virus 
from easily mutating. Thus, eff  orts to identify other CTL-
induced HIV-1 mutations in structurally important regions of 
Gag (or other proteins), and to defi  ne mechanisms by which 
these mutations infl  uence VL set point and disease progres-
sion will ultimately benefi  t the design of an AIDS vaccine. 1016 IN VIVO FITNESS COSTS ASSOCIATED WITH HIV-1 GAG CTL ESCAPE MUTATIONS | Goepfert et al.
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escape or reversion takes place because of HLA pressure in the subjects for 
which the sequences are observed. The likelihood of the observations was 
then maximized over the parameters of both models using an expectation-
maximization algorithm, and a p-value was computed using a likelihood ratio 
test based on those likelihoods. To increase power, the tests were binarized 
such the presence or absence of a given HLA allele was correlated with the 
presence or absence of a given amino acid. HLA polymorphism pairs were 
also analyzed only when the actual or expected count in every cell of the cor-
responding two-by-two contingency table was greater than or equal to three. 
For every amino acid at each position, the HLA allele with the strongest as-
sociation (and its corresponding p-value) was added to the list of identifi  ed 
associations. The analysis was repeated after removing individuals having or 
possibly having this HLA allele. This procedure was iterated until no HLA 
allele yielded an association with P   <   0.05. A q-value statistic, estimating the 
proportion of false positives among the associations identifi  ed, was computed 
for each association by repeating this analysis on null data. These q-value 
statistics were estimated separately for Gag and Nef associations using one 
million null tests per protein. Associations with q-values less than or equal to 
0.2 were deemed signifi  cant. 
  Analysis of HLA-I  –  associated HIV-1 polymorphisms in linked Zam-
bian transmission pairs.     HIV-1   gag   and   nef   sequences were analyzed in 
88 and 96 out of 114 Zambian transmission pairs, respectively. HIV-1 poly-
morphisms were defi  ned based on associations calculated in the South African 
cohort. Only predicted CTL escapes and attractions were analyzed. HLA-I 
associations that were either not present in the Zambian cohort or were asso-
ciated with less than or equal to one mutation were not included in the analy-
sis. In cases where more than one HLA-I was associated with a specifi  c 
polymorphism, the linked amino acid also associated with a known CTL epi-
tope was used. If no CTL association was present, then the HLA-I allele demon-
strating the greatest association with the HIV-1 polymorphism was used. 
The donor sequence was treated as the transmitted sequence, except in cases 
where the donor encoded an escape mutation and the recipient encoded the 
clade C consensus amino acid (69 out of 1,004, or 6.9%, of the mutations). 
  Statistics.     Comparisons between VL and the number of mutations were 
performed by the nonparametric Spearman rank correlation and Mann-
Whitney U tests. 
  Online supplemental material.     Table S1 lists HLA-I allele  –  associated 
HIV-1 polymorphisms not occurring within or near known CTL epitopes. 
Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20072457/DC1. 
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